Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 5, 2011, Pages 413-419

  Villegas, Maria Virginia ^a   Briceno, David Felipe ^a   Ruiz, Sory Jamil ^a   Furtado, Guilherme H ^b,c   Nicolau, David P ^b  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^b HARTFORD HOSPITAL   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Colombia; Drug resistance, bacterial; Gram negative bacteria; Monte Carlo Method; Pharmacology

Indexed keywords

CILASTATIN PLUS IMIPENEM; DORIPENEM; IMIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COLOMBIA; DRUG EXPOSURE; DRUG RESPONSE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; SIMULATION; STEADY STATE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLOMBIA; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 82855170888     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(11)70221-5     Document Type: Article

References (8)

1. Koomanachai P., Bulik C.C., Kuti J.L., et al. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010, 32:766-779.
2. Roberts J., Kwa A., Montakantikul P., et al. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: The PASSPORT Program - Asia-Pacific Region. Int J Antimicrob Agents 2011, 37(3):225-229.
3. DeRyke C.A., Kuti J.L., Nicolau D.P. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii. Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007, 27:333-342.
4. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nat Rev Microbiol 2004, 2:289-300.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Tenth Informational Supplement. CLSI document M100-S20-U. Wayne, PA: CLSI. 2010.
6. Doribax (doripenem for infection) [prescribing information]. Accessed July 19, 2010. http://www.doribax.com/doribax/shared/pi/doribax.pdf.
7. Villegas M.V., Lolans K., Correa A., et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006, 50:2880-2882.
8. Villegas M.V., Kattan J.N., Correa A., et al. Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob Agents Chemother 2007, 51:2001-2004.